WO1990006696A3 - Vaccin meningocoque de la proteine de la membrane externe de la classe 1 - Google Patents

Vaccin meningocoque de la proteine de la membrane externe de la classe 1 Download PDF

Info

Publication number
WO1990006696A3
WO1990006696A3 PCT/US1989/005678 US8905678W WO9006696A3 WO 1990006696 A3 WO1990006696 A3 WO 1990006696A3 US 8905678 W US8905678 W US 8905678W WO 9006696 A3 WO9006696 A3 WO 9006696A3
Authority
WO
WIPO (PCT)
Prior art keywords
membrane protein
protein vaccine
class
meningococcal class
meningococcal
Prior art date
Application number
PCT/US1989/005678
Other languages
English (en)
Other versions
WO1990006696A2 (fr
Inventor
Robert C Seid
Peter R Paradiso
Jan T Poolman
Peter Hoogerhout
Emmanuel J H J Wiertz
Peter Van Der Ley
John Edward Heckels
Ian Nicholas Clarke
Original Assignee
Praxis Biolog Inc
Rijksinst Volksgezond Milieuhy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27352237&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1990006696(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from NL8803111A external-priority patent/NL8803111A/nl
Application filed by Praxis Biolog Inc, Rijksinst Volksgezond Milieuhy filed Critical Praxis Biolog Inc
Priority to JP50166290A priority Critical patent/JP3436756B2/ja
Priority to EP90901397A priority patent/EP0449958B9/fr
Priority to DE68921895T priority patent/DE68921895T3/de
Publication of WO1990006696A2 publication Critical patent/WO1990006696A2/fr
Publication of WO1990006696A3 publication Critical patent/WO1990006696A3/fr
Priority to DK199101174A priority patent/DK175788B1/da
Priority to NO912369A priority patent/NO305463B1/no
Priority to FI912965A priority patent/FI113009B/fi
Priority to US08/204,808 priority patent/US7118757B1/en
Priority to US08/461,651 priority patent/US7238345B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Des vésicules de la membrane externe, des protéines de la membrane externe de classe 1 de Neisseria meningitidis, des fragments ou des oligopeptides contenant des épitopes des protéines de membrane externe de classe 1 peuvent être utilisés pour l'immunisation contre la maladie méningocoque.
PCT/US1989/005678 1988-12-19 1989-12-19 Vaccin meningocoque de la proteine de la membrane externe de la classe 1 WO1990006696A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP50166290A JP3436756B2 (ja) 1988-12-19 1989-12-19 髄膜炎菌のクラスｉの外膜タンパク質のワクチン
EP90901397A EP0449958B9 (fr) 1988-12-19 1989-12-19 Vaccin meningocoque de la proteine de la membrane externe de la classe 1
DE68921895T DE68921895T3 (de) 1988-12-19 1989-12-19 Meningococcales klasse i-aussenmembranprotein-vakzin.
FI912965A FI113009B (fi) 1988-12-19 1991-06-18 Menetelmä rokotteen valmistamiseksi Neisseria meningitidis-bakteeria vastaan sekä Neisseria meningitidis -kanta
NO912369A NO305463B1 (no) 1988-12-19 1991-06-18 FremgangsmÕte for fremstilling av en vaksine mot Neisseria meningitidis, klasse 2/3 minusmutant av Neisseria Neisseria meningitidis stamme, samt mikroorganisme som uttrykker et fusjonsprotein
DK199101174A DK175788B1 (da) 1988-12-19 1991-06-18 Vaccine imod meningococcussygdomme, deri indgående komponenter, disses anvendelse og rekombinanter, som eksprimerer dem
US08/204,808 US7118757B1 (en) 1988-12-19 1994-02-15 Meningococcal class 1 outer-membrane protein vaccine
US08/461,651 US7238345B1 (en) 1988-12-19 1995-06-05 Recombinant microorganism expressing meningococcal class 1 outer membrane protein

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
NL8803111A NL8803111A (nl) 1988-12-19 1988-12-19 Multivalent meningococcen klasse i buitenmembraaneiwit vaccin.
NL8803111 1988-12-19
NL8900030 1989-01-06
NL8900036A NL8900036A (nl) 1988-12-19 1989-01-06 Multivalent meningococcen klasse 1 buitenmembraaneiwit vaccin.
NL8901612A NL8901612A (nl) 1988-12-19 1989-06-26 Multivalent meningococcen klasse i buitenmembraaneiwit vaccin.
NL8901612 1989-06-26

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US07691005 A-371-Of-International 1989-12-19
US08/204,808 Continuation US7118757B1 (en) 1988-12-19 1994-02-15 Meningococcal class 1 outer-membrane protein vaccine

Publications (2)

Publication Number Publication Date
WO1990006696A2 WO1990006696A2 (fr) 1990-06-28
WO1990006696A3 true WO1990006696A3 (fr) 1990-07-12

Family

ID=27352237

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1989/005678 WO1990006696A2 (fr) 1988-12-19 1989-12-19 Vaccin meningocoque de la proteine de la membrane externe de la classe 1

Country Status (10)

Country Link
EP (1) EP0449958B9 (fr)
JP (1) JP3436756B2 (fr)
AT (1) ATE120093T1 (fr)
AU (1) AU640118B2 (fr)
DE (1) DE68921895T3 (fr)
DK (1) DK175788B1 (fr)
ES (1) ES2070312T5 (fr)
FI (1) FI113009B (fr)
NO (1) NO305463B1 (fr)
WO (1) WO1990006696A2 (fr)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7118757B1 (en) 1988-12-19 2006-10-10 Wyeth Holdings Corporation Meningococcal class 1 outer-membrane protein vaccine
NZ239643A (en) * 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
EP0967279B1 (fr) 1992-03-02 2008-01-02 Novartis Vaccines and Diagnostics S.r.l. Cytotoxine d' Helicobacter pylori utile dans des vaccins et en diagnostique
NL9201716A (nl) * 1992-10-02 1994-05-02 Nederlanden Staat Buitenmembraanvesikel dat voorzien is van een groep polypeptiden welke ten minste de immuunwerking van aan membraan gebonden buitenmembraaneiwitten (OMP's) hebben, werkwijze ter bereiding ervan alsmede een vaccin dat een dergelijk buitenmembraanvesikel omvat.
JPH08505128A (ja) * 1992-10-26 1996-06-04 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ，アズ リプリゼンテッド バイ ザ セクレタリー，デパートメント オブ ヘルス アンド ヒューマン サービシーズ ＮｅｉｓｓｅｒｉａｇｏｎｏｒｒｈｏｅａｅおよびＮｅｉｓｓｅｒｉａｍｅｎｉｎｇｉｔｉｄｉｓに対する免疫感作
PT624376E (pt) 1993-05-13 2000-07-31 American Cyanamid Co Preparacao e utilizacoes de proteinas de membranas externas deficitarias em los de cocos gram-negativos
US5439808A (en) * 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
US6153406A (en) * 1993-07-23 2000-11-28 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane protein P2 from Haemophilus influenzae type B
US5747287A (en) * 1995-04-28 1998-05-05 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
US5811102A (en) 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines
CA2182637A1 (fr) * 1995-08-04 1997-02-05 Jagath L. Kadurugamuwa Vaccins et compositions pharmaceutiques utilisant les vesicules de membranes de microorganismes; methodes de preparation
US20020028215A1 (en) 1999-08-09 2002-03-07 Jagath L. Kadurugamuwa Novel vaccines and pharmaceutical compositions using membrane vesicles of microorganisms, and methods for preparing same
PL325604A1 (en) * 1995-09-18 1998-08-03 Us Army Med Res Mat Command Improved methods of obtaining non-covalently complexed and multvalent proteosomal subunitary vaccines
EP0909323B1 (fr) 1996-01-04 2007-02-28 Novartis Vaccines and Diagnostics, Inc. Bacterioferritine de helicobacter pilori
GB9611673D0 (en) * 1996-06-05 1996-08-07 Peptide Therapeutics Ltd Meningococcal vaccine
JP4150082B2 (ja) 1996-08-27 2008-09-17 カイロン コーポレイション 独特の髄膜炎菌性ｂエピトープを規定するモノクローナル抗体およびワクチン組成物の調製におけるそれらの使用
US6558677B2 (en) * 1996-10-15 2003-05-06 Wendell D. Zollinger Vaccine against gram negative bacteria
GB9701489D0 (en) 1997-01-24 1997-03-12 Auspharm Int Ltd Antigen
EP2261347A3 (fr) * 1998-05-01 2012-01-11 Novartis Vaccines and Diagnostics, Inc. Antigènes de Neisseria meningitidis et compositions
CA2332963C (fr) * 1998-05-29 2013-07-23 Chiron Corporation Vaccin mixte b/c contre la meningite
EP1741443B1 (fr) * 1998-05-29 2014-05-21 Novartis Vaccines and Diagnostics, Inc. Vaccin B/C combiné contre la méningite
AU2003213540B8 (en) * 1998-05-29 2006-09-28 Novartis Vaccines And Diagnostic Inc. Combination meningitidis B/C vaccines
GB9814902D0 (en) * 1998-07-10 1998-09-09 Univ Nottingham Screening of neisserial vaccine candidates against pathogenic neisseria
US7252828B2 (en) 1998-07-15 2007-08-07 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
US6693186B2 (en) * 1998-09-01 2004-02-17 Antex Biologics Inc Neisseria meningitidis polypeptide, nucleic acid sequence and uses thereof
US6756493B1 (en) 1998-09-01 2004-06-29 Antex Biologics, Inc. Nucleic acid sequence and uses thereof
US10967045B2 (en) 1998-11-02 2021-04-06 Secretary of State for Health and Social Care Multicomponent meningococcal vaccine
GB9823978D0 (en) * 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
CA2359492A1 (fr) 1999-01-15 2000-07-20 Smithkline Beecham Biologicals S.A. Antigene de neisseria meningitidis
NZ581940A (en) 1999-04-30 2011-07-29 Novartis Vaccines & Diagnostic Conserved neisserial antigens
EP1069133A1 (fr) * 1999-07-13 2001-01-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compositions a base de Neisseria meningitidis et leur utilisation comme agents anti-infectieux
GB9916529D0 (en) * 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
GB9918319D0 (en) * 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
CN1433470A (zh) * 1999-10-29 2003-07-30 启龙股份公司 奈瑟球菌的抗原性肽
JP4840956B2 (ja) * 1999-11-29 2011-12-21 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル ８５ｋＤａのナイセリア抗原
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
DK1112747T3 (da) * 1999-12-28 2004-10-25 Akzo Nobel Nv Salmonellavaccine, som ikke inducerer antistoffer mod flagellin eller flageller
DK1248647T3 (da) * 2000-01-17 2010-09-27 Novartis Vaccines & Diagnostic Ydre membranvesikel (OMV) vaccine omfattende N. meningitidis serogruppe B ydre membranproteiner
NZ520445A (en) * 2000-01-25 2004-02-27 Univ Queensland Proteins comprising conserved regions of neisseria meningitidis surface antigen NhhA
PT1947187E (pt) 2000-02-28 2011-07-04 Novartis Vaccines & Diagnostic Expressões híbridas de proteínas de neisseria
MXPA03000822A (es) * 2000-07-27 2004-11-01 Childrens Hosp & Res Ct Oak Vacunas para proteccion de espectro amplio contra enfermedades causadas por neisseria meningitidis.
GB0103170D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
EP2332581B1 (fr) 2001-01-23 2015-07-01 Sanofi Pasteur Inc. Vaccin de meningocoque tri- ou tetravalent préparé avec un conjugué de polysaccharide et de CRM197
WO2002083711A2 (fr) 2001-04-17 2002-10-24 Chiron Corporation Mimetiques moleculaires d'epitopes b meningococciques qui elicitent des anticorps fonctionnellement actifs
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
GB0130123D0 (en) * 2001-12-17 2002-02-06 Microbiological Res Agency Outer membrane vesicle vaccine and its preparation
US7405039B2 (en) 2002-02-07 2008-07-29 Austin Health Viral variants with altered susceptibility to nucleoside analogs and uses thereof
EP2455390A1 (fr) 2002-04-12 2012-05-23 Melbourne Health Variantes de l'hépatite B virale avec une susceptibilité réduite aux analogues nucléosides et utilisations associées
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
SI2351579T1 (sl) 2002-10-11 2017-05-31 Glaxosmithkline Biologicals Sa Polipeptidna cepiva za široko zaščito proti hipervirulentnim meningokoknim linijam
AU2003295520B8 (en) 2002-11-12 2011-05-19 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for Staphylococcal infections
AU2003290867A1 (en) 2002-11-12 2004-06-03 The Brigham And Women's Hospital, Inc. Methods and products for treating staphylococcal infections
US20070059329A1 (en) 2002-11-15 2007-03-15 Nathalie Norais Unexpected surface proteins in meningococcus
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
CN101926988B (zh) 2003-01-30 2014-06-04 诺华疫苗和诊断有限公司 抗多种脑膜炎球菌血清组的可注射性疫苗
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
WO2005042564A1 (fr) * 2003-10-20 2005-05-12 Sidney Kimmel Cancer Center Proteines de fusion flagelline, comme adjuvants ou vaccins, et procedes d'utilisation
ES2415358T3 (es) 2004-04-21 2013-07-25 The Brigham And Women's Hospital, Inc. Péptidos de fijación a la poli-N-acetil glucosamina (PNAG/DPNAG) y procedimientos para el uso de los mismos
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
PT2682126T (pt) 2005-01-27 2017-02-28 Children`S Hospital & Res Center At Oakland Vacinas de vesícula com base em agn1870 para proteção de amplo espetro contra doenças causadas por neisseria meningitidis
US8211443B2 (en) 2005-04-08 2012-07-03 Melbourne Health Variants of hepatitis B virus with resistance to anti-viral nucleoside agents and applications thereof
EP1874923A4 (fr) 2005-04-08 2010-08-04 Melbourne Health Variantes du virus de l'hépatite b présentant une résistance aux agents de nucléotide anti-virale et application de ces variantes
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
GB0611914D0 (en) 2006-06-15 2006-07-26 Teti Giuseppe Peptides that mimic non-human cross-reactive protective epitopes of the group Bmeningococcal capsulsar polysaccharide
EP2886551A3 (fr) 2008-02-21 2015-09-23 Novartis AG Polypeptides fHbp méningococciques
GB0809659D0 (en) * 2008-05-28 2008-07-02 Univ Nottingham Polypeptides
RU2477145C2 (ru) 2008-05-30 2013-03-10 ДЗЕ Ю.Эс.Эй., ЭС РЕПРЕЗЕНТЕД БАЙ ДЗЕ СЕКРЕТАРИ ОФ ДЗЕ АРМИ, ОН БЕХАФ ОФ УОЛТЕР РИД АРМИ Мультивалентная вакцина из нативных везикул наружной мембраны менингококков, способы ее получения и применения
RU2532911C2 (ru) 2008-07-21 2014-11-20 Дзе Брихэм Энд Уимен'З Хоспитал, Инк. Способы и композиции, относящиеся к синтетическим бета-1,6-глюкозаминолигосахаридам
WO2010027499A2 (fr) * 2008-09-05 2010-03-11 University Of Massachusetts Medical School Procédés, compositions et vaccins se rapportant à des anticorps anti- neisseria meningitidis
EP2470204B1 (fr) 2009-08-27 2015-12-16 GlaxoSmithKline Biologicals SA Polypeptides hybrides contenant des séquences fhbp à méningocoques
WO2011039631A2 (fr) 2009-09-30 2011-04-07 Novartis Ag Expression de polypeptides fhbp méningococciques
BR112012010531A2 (pt) 2009-10-27 2019-09-24 Novartis Ag "polipeptídeos de modificação meningocócica fhbp"
BR112013005626B1 (pt) 2010-09-10 2022-07-26 Glaxosmithkline Biologicals Sa Meningococo, processo para a preparação de uma cepa meningocócica, vesículas de membrana externa, composição farmacêutica imunogênica, e, uso de uma composição
JP2012090571A (ja) * 2010-10-27 2012-05-17 Sekisui Chem Co Ltd 動物の免疫方法、免疫用組成物、抗体の製造方法、並びに、ハイブリドーマの製造方法
NZ630133A (en) 2012-06-14 2016-10-28 Novartis Ag Vaccines for serogroup x meningococcus
HUE052293T2 (hu) 2014-02-28 2021-04-28 Glaxosmithkline Biologicals Sa Módosított fHbp meningococcus-polipeptidek
JP6827322B2 (ja) * 2014-04-17 2021-02-10 コーニング インコーポレイテッド 生物学的存在の増殖のための容器
MX2017001279A (es) * 2014-07-30 2017-08-07 Cleveland Biolabs Inc Usos y composiciones de la flagelina.
JP2023542141A (ja) * 2020-09-15 2023-10-05 ザ ユニバーシティー オブ モンタナ 繊維状バクテリオファージを標的化する組成物および方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0090660A2 (fr) * 1982-03-30 1983-10-05 THE UNITED STATES OF AMERICA as represented by the Secretary of The United States Department of Commerce Vaccin anti-gonococcique
EP0145359A2 (fr) * 1983-11-21 1985-06-19 The Wellcome Foundation Limited Complexes, leur procédé de préparation et formulations les contenant
US4601903A (en) * 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US4673574A (en) * 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
EP0301992A2 (fr) * 1987-07-30 1989-02-01 Centro Nacional De Biopreparados Vaccin contre Neisséria meningitidis groupe B, gammaglobuline et facteur de transfert
WO1989010967A1 (fr) * 1988-05-05 1989-11-16 Praxis Biologics, Inc. Vaccins de flagelline recombinants

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4673574A (en) * 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
EP0090660A2 (fr) * 1982-03-30 1983-10-05 THE UNITED STATES OF AMERICA as represented by the Secretary of The United States Department of Commerce Vaccin anti-gonococcique
EP0145359A2 (fr) * 1983-11-21 1985-06-19 The Wellcome Foundation Limited Complexes, leur procédé de préparation et formulations les contenant
US4601903A (en) * 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
EP0301992A2 (fr) * 1987-07-30 1989-02-01 Centro Nacional De Biopreparados Vaccin contre Neisséria meningitidis groupe B, gammaglobuline et facteur de transfert
WO1989010967A1 (fr) * 1988-05-05 1989-11-16 Praxis Biologics, Inc. Vaccins de flagelline recombinants

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
Biological Abstracts, Volume 87, 1989 H. ABDILLAHI et al.: "Microbiol. Immunol. 47(3): 139-144. 1988. Definition of Meningococcal Class 1 OMP Sybtyping Antigens by Monoclonal Antibodies", see Abstract No. 115445 *
Biological Abstracts/RRM, BR36:126147, AN 89:258923, E.J.H.J. WIERTZ et al.: "Human T-Cell Epitope Mapping of the Meningococcal Class 1 Outer Membrane Protein", Ici Pharmaceuticals-Ucla (University of California-Los Angeles) Symposium on Immunogenicity, Steamboat Springs, Colorado, USA, January 21-28, 1989. & J Cell Biochem Suppl 0 (13 Part A). 1989. 326. *
CHEMICAL ABSTRACTS, Volume 94, No. 25, 22 June 1981, American Chemical Society, (Columbus, Ohio, US), C.-M. TSAI et al.: "Five Structural Classes of Major Outer Membrane Proteins in Neisseria Meningitidis", see page 281* Abstract 205111z, & J. Bacteriol. 1981, 146(1), 69-78 (ENG)* *
Infection and Immunity, Volume 40, No. 1, April 1983, American Society for Microbiology, E.C. BEUVERY et al.: "Preparation and Physicochemical and Immunological Characterization of Polysaccharide-Outer Membrane Protein", pages 369-380 *
Infection and Immunity, Volume 46, No. 2, November 1984, American Society for Microbiology, L. WANG et al.: "Development of a Neisseria Meningitidis Group B Serotype 2b Protein Vaccine and Evaluation in a Mouse Model", pages 408-414 *
Infection and Immunity, Volume 54, No. 2, November 1986, American Society for Microbiology, W. JISKOOT et al.: "Immunogenic Activity of Gonococcal Protein I in Mice with Three Different Lipoidal Adjuvants Delivered in Liposomes", pages 333-338 *
Infection and Immunity, Volume 55, No. 11, November 1987, American Society for Microbiology, A.K. BARLOW et al.: "Molecular Cloning and Expression of Neisseria Meningitidis Class 1 Outer Membrane Protein in Escherichia Coli k-12", pages 2734-2740 *
Infection and Immunity, Volume 57, No. 3, March 1989, American Society for Microbiology, J.T. POOLMAN et al.: "Purification, Cyanogen Bromide Cleavage, and Amino Terminus Sequencing of Class 1 and Class 3 Outer Membrane Proteins of Memingococci", pages 1005-1007 *
Journal of Bacteriology, Volume 141, No. 1, January 1980, CHAO-MING TSAI et al.: "Chemical Analysis of Major Outer Membrane Proteins of Neisseria Meningitidis: Comparison of Serotypes 2 and 11", pages 169-176 *
Journal of Immunological Methods, Volume 113, 1988, Elsevier Science Publishers B.V. (Biomedical Division) E. WEDEGE et al.: "Restoration of Antibody Binding to Blotted Meningococcal Outer Membrane Proteins using Various Detergents", pages 51-59 *
Vaccine, Volume 5, No. 2, 5 June 1987, Butterworth & Co. (Publishers) Ltd, (Guildford, Surrey, GB), G. GREGORIADIS et al.: "Liposomes as Immunological Adjuvants: Antigen Incorporation Studies", pages 145-151 *
Vaccine, Volume 5, No. 4, 5 December 1987, Butterworth & Co. (Publishers) Ltd, (London, GB), T. TEERLINK et al.: "Synergistic Effect of Detergents and Aluminium Phosphate on the Humoral Immune Response to Bacterial and Viral Membrane Proteins", pages 307-314 *

Also Published As

Publication number Publication date
JP3436756B2 (ja) 2003-08-18
ES2070312T3 (es) 1995-06-01
ES2070312T5 (es) 2003-05-16
ATE120093T1 (de) 1995-04-15
WO1990006696A2 (fr) 1990-06-28
JPH06503465A (ja) 1994-04-21
FI113009B (fi) 2004-02-27
EP0449958A1 (fr) 1991-10-09
DK175788B1 (da) 2005-02-21
EP0449958B1 (fr) 1995-03-22
DE68921895T2 (de) 1995-09-07
DE68921895D1 (de) 1995-04-27
EP0449958B2 (fr) 2002-11-13
AU640118B2 (en) 1993-08-19
DK117491A (da) 1991-08-15
NO305463B1 (no) 1999-06-07
DK117491D0 (da) 1991-06-18
NO912369L (no) 1991-08-06
NO912369D0 (no) 1991-06-18
FI912965A0 (fi) 1991-06-18
AU4821990A (en) 1990-07-10
EP0449958B9 (fr) 2003-05-28
DE68921895T3 (de) 2003-05-22

Similar Documents

Publication Publication Date Title
WO1990006696A3 (fr) Vaccin meningocoque de la proteine de la membrane externe de la classe 1
AU657487B2 (en) Nucleotide sequence coding for an outer membrane protein from neisseria meningitidis and use of said protein in vaccine preparations
NO951181D0 (no) Immunogen menigokokk-LPS, ytter-membranvesikler, samt vaksine fremstilt derav
EP0117783A3 (fr) Vaccin couplé de l'haemophilus influenzae type B
EP1378245A3 (fr) Protéines de liaison de transferrine de neisseria gonorrhoeae et neisseria meningitidis. Leur utilisation comme vaccin
NO912825D0 (no) Fremgangsmaate for fremstilling av cokonjugate vaksiner omfattende immunogenisk protein, hiv-beslektede peptider og anioniske grupper.
DE69031351T2 (de) Zubereitungen und behandlungen von pneumonia in tieren
AU3313789A (en) Haemophilus influenza type B oxidized polysaccharide-outer membrane protein conjugate vaccine
CA2007248A1 (fr) Vaccin antimeningococcique de classe 1 contenant une proteine de la membrane exterieure du meningocoque
NO892015D0 (no) Fremgangsmaate for fremstilling av et legemiddel.
NO912823L (no) Fremgangsmaate for fremstilling av klasse ii-proteinet av neisseria meningitidis samt vaksiner som inneholder dette.
NO912822L (no) Fremgangsmaate for fremstilling av klasse ii-proteinet frayttermembranen til neisseria meningitidis.
NO912824L (no) Fremgangsmaate for fremstilling av klasse ii-proteinet frayttermembranen til neisseria meningitidis.
AU7614798A (en) High level expression, purification and refolding of the Neisseria meningitidis outer membrane group B porin proteins
ZA915627B (en) The class ii protein of the outer membrane of neisseria meningitidis having immunologic carrier and enhancement properties,and vaccines containing same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU DK FI JP NO US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE ES FR GB IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU DK FI JP NO US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE ES FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1990901397

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 912965

Country of ref document: FI

WWP Wipo information: published in national office

Ref document number: 1990901397

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1990901397

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 912965

Country of ref document: FI